Indication

Fabry disease

Fabry disease is a rare, inherited X-linked lysosomal storage disorder caused by pathogenic variants in the GLA gene that lead to a deficiency of the enzyme alpha-galactosidase A. Read more about Fabry disease

3 drugs 3 manufacturers

Advertisement

Drugs that treat it

Common Fabry disease therapies.

Showing 1–3 of 3 drugs

Filter & compare in the drug finder →Opens the drug finder with Fabry disease preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Fabry disease.

Fabry disease is a rare, inherited X-linked lysosomal storage disorder caused by pathogenic variants in the GLA gene that lead to a deficiency of the enzyme alpha-galactosidase A.

This enzymatic defect results in progressive intracellular accumulation of globotriaosylceramide and related glycosphingolipids within vascular endothelial cells and visceral tissues throughout the body.

Clinical manifestations typically include episodic neuropathic extremity pain, cutaneous angiokeratomas, hypohidrosis, and corneal verticillata, which often emerge during childhood or adolescence.

If untreated, the condition can progress to life-threatening multisystem complications in adulthood, most notably cardiomyopathy, progressive renal impairment culminating in end-stage kidney disease, and early stroke.

Personalize your experience

Follow Fabry disease and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it